FREDERICK, MARYLAND, April 30, 2026
Theradaptive has received U.S. Food and Drug Administration (FDA) authorization to advance its OASIS clinical program into a pivotal Phase 3 trial, evaluating OsteoAdapt® SP, a next-generation bone regeneration therapeutic for spinal fusion procedures. This milestone marks a critical step toward premarket approval (PMA) and potential U.S. commercialization, positioning the company at the forefront of innovative orthobiologic solutions. The therapy is designed to address degenerative spinal diseases, a condition affecting millions globally, and aims to provide a safer and more effective alternative to traditional bone grafting techniques.
Pivotal OASIS Trial Targets Spinal Fusion Innovation
The OASIS Phase 3 clinical trial will evaluate OsteoAdapt SP across multiple surgical procedures, including Transforaminal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), and Lateral Lumbar Interbody Fusion (LLIF). These procedures are commonly performed to treat degenerative conditions of the lumbosacral spine, which contribute significantly to chronic lower back pain and reduced quality of life.
OsteoAdapt SP is being studied as a replacement for autologous and allograft bone grafts, which are currently standard but often associated with limitations such as donor site complications and inconsistent outcomes. Notably, Theradaptive is the only company conducting Investigational Device Exemption (IDE) studies across all three major spinal fusion indications, highlighting its leadership in comprehensive spinal regenerative therapy development.
Advanced AMP2™ Technology Drives Targeted Bone Regeneration
Advertisement
OsteoAdapt SP is powered by Theradaptive’s proprietary AMP2™ technology, a recombinant rhBMP-2 variant engineered for targeted and sustained bone regeneration. Unlike conventional bone graft substitutes, this approach is designed to minimize off-target effects while enhancing localized therapeutic activity, addressing key challenges in current spinal fusion treatments. Early clinical experience involving approximately 100 participants has demonstrated promising results, supporting the progression to a pivotal trial.
The technology enables precise delivery of biologic signals to the fusion site, improving the likelihood of successful bone healing and long-term stability. This innovation reflects a broader shift toward precision regenerative medicine, where therapies are tailored to optimize both efficacy and safety outcomes in complex surgical settings.
Expanding MedTech Innovation and Market Opportunity
The FDA’s approval to initiate the pivotal trial underscores the growing demand for advanced orthobiologic therapies, particularly as degenerative spinal conditions continue to rise with aging populations. Approximately 80% of adults experience lower back pain during their lifetime, and the global bone graft substitute market is projected to exceed $5 billion by the early 2030s, creating significant opportunities for innovative solutions like OsteoAdapt SP.
From a GxP perspective, the OASIS trial will adhere to Good Clinical Practice (GCP) and medical device regulatory standards, ensuring high-quality data, patient safety, and compliance throughout the study. The successful completion of this trial could pave the way for FDA PMA approval, enabling Theradaptive to disrupt a long-standing market dominated by legacy products. As healthcare systems increasingly prioritize minimally invasive and biologically advanced treatments, OsteoAdapt SP has the potential to transform spinal fusion outcomes, offering patients a more effective, targeted, and durable solution for degenerative spine disorders while reinforcing Theradaptive’s position as a leader in next-generation regenerative MedTech innovation.
Source: Theradaptive press release
